Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Latest News

Market capUnder $500B
All Over $50MOver $300MOver $2BOver $10B
All Under $1BUnder $10BUnder $100BUnder $500B
SectorsAll
Filter by sector
Thursday, October 15, 2026· 8792 stock ideas· 217 writers·
15,593 views· 7,381 clicks

[scuttleslops] MRVL, APP, AMZN, Chips

Marvell is positioning networking, optical connectivity and server-management chips as AI data centers link GPUs, custom accelerators and racks, lifting five-year targets.

MRVL $241B
scuttleblurb 5 clicks

From X

@calvinblissett

Calvin Blissett on X

$CCLD crazy important earnings. Questions and things to monitor: new AI products, cybersecurity any and all information (loss of sales momentum, loss of current clients, still covered by insurance, lawsuits), why no acquisitions, are they still focused on acquisitions or spending more time developing AI products, is the person leading the AI strategy fit to lead it? At what point are buybacks considered despite the phenomenal ROI from acquisition.
@gnoble79

George Noble on X

Attention $OPEN army. I could not have been any more explicit and persistent in urging you to sell your $OPEN at 8 one year ago. You did not listen. Instead I was met with profane invective. They say revenge is a dish best served cold. It is indeed. The ridicule was loud. The analysis was weak. The result was decisive. Some arguments are best settled by the scoreboard. The media is complicit for promoting this garbage. The Noble Update has generated a long/short spread of 63% from selecting longs and shorts over the last year. I Check it out. You want performance? We got this. @natbrunell @philrosenn @APompliano @ericjackson @rabois @MebFaber @dayetweets @MarkNeuman18 @nejatian @piovincenzo_ @MollySOShea @shaneparrish @JonErlichman @Mindset4Money_X @cvpayne @SaraEisen @carlquintanilla @michaelsantoli @jonathanrstern
@StableBread 1 click

Fajasy on X

I tried to work out who’s behind the AI data labeling companies that approached Nubeva Technologies $NBVAF (TSXV: $NBVA). CEO Randy Chou didn’t name the data labeling companies (firms that turn experts’ knowledge into training data for AI labs) or the customers behind them. “If a data labeling company’s coming to us, somebody behind them is asking,” Chou said, adding that the customer typically isn’t limited to cybersecurity companies. OpenAI is one potential candidate, since my previous write-up concluded that the frontier model Nubeva got access to in September was most likely OpenAI’s, through its Daybreak program for vetted defenders. OpenAI launched GPT-6 Astra on September 3, 2026, the day Nubeva announced its access. It’s the first model OpenAI rated Critical for cybersecurity capability. But access to OpenAI’s model wouldn’t prove OpenAI is also behind the data labeling companies, since any lab building cyber models could want labeled malware. Among data labeling companies, three of the largest are publicly recruiting or selling binary analysis expertise, the skill of figuring out what malware programs do: → Scale AI: Its product manager posting calls the cybersecurity portfolio “a product line that does not exist yet” and says the hire will recruit “malware analysts.” → Turing: Sells CyberBench, security tasks for training and testing frontier models, with malware analysis and reverse engineering among its ten categories. TechCrunch called Turing “a key coding provider for OpenAI” in March 2025. → Mercor: Recruits security experts, preferring reverse engineering or binary analysis backgrounds, and counts OpenAI, Anthropic, and Meta $META as customers. OpenAI cut ties with Scale in June 2025, after Meta bought 49% of Scale and hired its founder, Alexandr Wang. So if OpenAI is behind the approach, Turing and Mercor are the likeliest data labeling companies, since both sell to OpenAI and already sell or buy binary analysis expertise. Either way, these data labeling companies are worth $2.2-29B, so even Turing, the smallest, could pay the top of my $12-19M sale range for Nubeva for less than 1% of its last valuation.

Investor Letters

All letters

Free Recaps of the best new stock ideas, delivered every morning.

Read past recaps
BNTC · long

Benitec Biopharma INC

Benitec Biopharma's BB-301 gene therapy is in a Phase 1b/2a trial for an ultra-rare muscular dystrophy.

BNTC $316M
Value Investors Club

British American Tobacco: Harvest

British American Tobacco’s U.S. reset revives combustibles and rebuilds its nicotine-pouch portfolio after legacy-brand writedowns and Velo…

BTI $121B
Invariant 5 clicks

Practical Parametric Yield

Cerebras’s WSE-3 faces parametric-yield constraints that could restrict supply, making power and clock-speed tradeoffs central to its next…

CBRS $39B
Irrational Analysis 3 clicks

Have a source we’re missing? Send your pick

Recent recaps

Latest recap

Wednesday, October 14 70 stock ideas
  • October 2026 Random Ramblings Yet Another Value Podcast
  • Visa: Unpacking The 7 Powers And Forward Valuation Ahead Of Q4 Earnings Seeking Alpha
Read the recap

All recaps

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 107

YouTube 4

Blogs 17

Seeking Alpha 49 of 225

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

88 accounts
Nominate an account

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.

Anything we’re missing?

Send us a pick